毕马威料香港上半年新股集资额695亿元位列全球第三
毕马威发表报告,预计2019上半年香港IPO市场共录得74宗新股上市,集资额达695亿元,仅次於纽约证券交易所和纳斯达克,位列全球新股市场第三。
今年上半年,生命科学行业领跑香港IPO市场,共募集资金达161亿元,其中已录得盈利的企业及新上市机制下尚未取得收入的生物科技企业分别各占三家。
香港新股市场活跃,录得超过190宗新股上市申请,为历史最高水平。毕马威维持此前预测,预计2019年总集资额规模将超过2,000亿元,新股总数达200宗。该行相信,创新科技企业上市仍是下半年香港IPO市场的焦点。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.